Appointed in December, 2009 to the board, he has now been selected to lead the board's audit committee -- in a move to improve corporate governance, there -- and is likely thus designated the Audit Committee's "financial expert" on Genzyme's board, under applicable SEC rules.
I would hope -- now out from under the constant vigilance (and myriad pressures?) of Messrs. Hassan and Becherer (at legacy Schering-Plough) -- that he will show true independence at Genzyme. This is from BostonGlobe.com, this morning:
. . . .the Cambridge biotechnology company said that it has taken steps to strengthen the role of its lead independent director and that it has appointed new leadership to head the board's audit committee. . . .
New board director Robert Bertolini, the former executive vice president and chief financial officer at Schering-Plough, was also appointed to chair the Audit Committee, Genzyme said. . . .
The actions, the company said, were designed to strengthen Genzyme's corporate governance. . . .
I can think of quite a few things to say here -- but I'll simply say "We shall see."